Dear Colleagues,

On behalf of the Jordanian Oncology Society Executive Committee, it is my pleasure to welcome you to the “Highlights of ASCO 2015” conference at the Movenpick Dead Sea Hotel.

We will be reviewing the most important, practice changing data presented at ASCO 2015, and particularly how the results may change the current standard of care. It will also be a good opportunity for us, especially colleagues who were not able to attend the ASCO 2015 meeting, to discuss the clinical implications of the presented data within the current standards of care in an interactive setting.

We wish you a fruitful enjoyable experience and look forward to your active participation.

Sincerely,

Sana Al Sukhun, MD, MSc.
JOS president.
Improving Health Outcomes through Education & Collaboration

Schedule at a Glance

Thursday, July 30, 2015

6:30pm - 7:00pm
Registration and Reception

7:00pm - 7:10pm
Welcome & Chair remarks.

7:10pm - 7:40pm
Keynote Talk

7:40pm - 8:30pm
Patient and Survivor Care

9:00 pm - 11:00 pm
Dinner

Friday, July 31, 2015

9:00am - 10:00am
Lung Cancer – Non-Small Cell

10:00am - 11:00am
Breast Cancer-Targeted therapy

11:00am - 11:15am
Break

11:15am - 11:30am
Breast Cancer-Cytotoxic Chemotherapy

11:30am - 12:10pm
Breast Cancer-Local Therapy

12:10pm - 2:30pm
Lunch and Friday prayers.

2:30pm - 3:00pm
Gastrointestinal (Colorectal) Cancer

3:00pm - 3:40pm
Gastrointestinal (Noncolorectal) Cancer

3:40pm - 4:00pm
Break

4:00pm - 05:15am
Melanoma, Skin cancer

06:00pm - 10:00pm
Dinner

Saturday, August 01, 2015

9:00am - 10:00am
Head and Neck Cancer

10:00am - 10:35am
Genitourinary (Prostate) Cancer

10:35am - 11:00am
Break

11:00am - 12:00pm
Lymphoma and Plasma Cell Disorders

6:30pm - 7:00pm
Registration and Reception

7:00pm - 7:10pm
Welcome & Chair remarks.

7:10pm - 7:40pm
Keynote Talk

7:40pm - 8:30pm
Patient and Survivor Care

9:00 pm - 11:00 pm
Dinner
6:30pm - 7:00pm  Registration and Reception  
Speaker: Sana Al Sukhun, MD, MSc

7:00pm - 7:10pm  Welcome & Chair remarks.  
Speaker: Sana Al Sukhun, MD, MSc

7:10pm - 7:50pm  Keynote Talk  
Moderators: Sana Al Sukhun, MD, MSc, and Abdallah Abbadi, MD

7:40pm - 7:50pm  Discussion

7:50pm - 8:30pm  Patient and Survivor Care  
Moderators: Ahmad Telhah, MD and Fayez Tbeishat, MD

7:50pm - 8:05pm  Speaker: Sameh Hashem, MD

- Abstract 8005: Whole brain radiotherapy for brain metastases from non-small lung cancer: Quality of life (QoL) and overall survival (OS) results from the UK Medical Research Council QUARTZ randomised clinical trial (ISRCTN 3826061). (Paula Mary Mulvenna).

8:05pm - 8:20pm  Speaker: Mohammad Salameh, MD

- Abstract 9501: CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. (Andrew Louis)
- Abstract 504: Adjuvant denosumab in breast cancer: Results from 3,425 postmeno pausal patients of the ABCSG-18 trial. (Michael Gnant, Himelstein)

8:20pm - 8:30pm  Discussion

9:00pm - 11:00pm  Dinner
9:00am - 10:00am Lung Cancer – Non-Small Cell
Moderators: Fadi Farhat, MD and Kholoud Al-qasem, MD
9:00am - 9:45am
Speaker: Rolf Stahel, MD
• Abstract 8001: Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts). (Leica V. Sequist)
• Abstract 8006: Internim results of a phase 2 study of the BRAF inhibitor (BRAHi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC). (David Planchard)
• Abstract 7500: Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701MAPS randomized phase 3 trial. (Gerard Zalcman)
• Abstract 7506: Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsquamous non-small cell lung cancer (mNSCLC) (Suresh Senan)
9:45am - 10:00am Discussion
10:00am - 11:00am Breast Cancer-Targeted Therapy
Moderators: Salah Abbasi, MD and Sami Rabadi, MD
10:00am - 10:30am
Speaker: Sana Al Sukhun, MD, MSc.
• Abstract LBA502: PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. (Nicholas Turner)
• Abstract 507: Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC. Primary results from the MARIANNE study. (Paul Anthony Ellis), receptor negative early breast cancer. (Marco Colleoni)
• Abstract 508: Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET). (Arlene Chan).

10:30am - 10:45am
Speaker: Hazem Abdulellah, MD

• Abstract 1003: Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). (Tiffany A. Traina).

10:45am - 11:00am
Discussion

11:00am - 11:15am
Break

11:15am - 11:30am
Breast Cancer-Cytotoxic Chemotherapy

Moderators: Tahseen Al-Rubaie, MD

• Abstract 1001: Phase III trial of etirinotecan pegol (EP) versus Treatment of Physician’s Choice (TPC) in patients with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C): The BEACONstudy. (Edith A. Perez)

• Abstract 1002: Low dose oral cyclophosphamide-methotrexate maintenance for receptor negative early breast cancer. (Marco Colleoni)

11:30am - 12:10pm
Breast Cancer-Local Therapy

Moderators: Mohmoud Al Masri, MD and Sami Khatib, MD

• Abstract 1006: The survival benefit offered by the surgical management of low-grade ductal carcinoma in situ of the breast. (Yasuaki Sagara).

11:45am - 12:00pm
Discussion

12:00pm - 12:10pm
Discussion

12:10pm - 2:30pm
Lunch and Friday prayers
2:30pm - 3:00pm  
**Gastrointestinal (Noncolorectal) Cancer**

Moderators: Majdi Barakat, MD and Nabil Alloush, MD

2:30pm - 2:45pm
Speaker: Fadi Farahat, MD

- **Abstract 4005:** Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance). (Matthew H. Kulke)

2:45pm - 3:00pm
Speaker: Kholoud Al-qasem, MD

- **Abstract 4000:** Phase 3, randomized, double-blind, multicenter, placebo-controlled trial of rilotumumab (R) plus epirubicin, cisplatin, and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The RILOMET-1 study. (David Cunningham)

3:00pm - 3:40pm  
**Gastrointestinal (Colorectal) Cancer**

Moderators: Rasmi Mubaideen, MD, and Ghadeer Abdeen, MD

3:00pm - 3:15pm
Speaker: Abdulmajeed Dayyat, MD

- **Abstract 3500:** A multi-center randomized controlled trial of mFOLFOX6 with or without radiation in neoadjuvant treatment of local advanced rectal cancer (FOWARC study): Preliminary results. (Yanhong Deng)

3:15pm - 3:30pm
Speaker: Lina Marei, MD

- **Abstract 3503:** Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB/SWOG 80405 (Alliance).
- **Abstract 3504:** Impact of aspirin as secondary prevention in an unselected cohort of 25,644 patients with colorectal cancer: A population-based study. (Simer Bains).

3:30pm - 3:40pm
Discussion

3:40pm - 4:00pm  
**Break**
Friday
July 31
2015
4:00pm - 4:30pm
Melanoma, Skin Cancer
Moderators: Salah Halasseh, MD and Sameer Hazer, MD
4:00pm - 4:15pm
Speaker: Luqman Soliman, MD
-Abstract LBA1: CheckMate 067: A phase III randomized double-blind study of nivolumab monotherapy or NIVO combined with ipilimumab versus PRI monotherapy in previously untreated patients with advanced melanoma. (Jedd D. Wolchok).
-Abstract 9005: Long term efficacy of pembrolizumab (pembro, MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. (Adil Daud)
4:15pm - 4:30pm
Speaker: Mahmoud Al Masri, MD
-Abstract 9001: Long term follow up of survival in a randomised trial of wide or narrow excision margins in high risk primary melanoma. (Andrew J Hayes)
-Abstract LBA9002: Survival of SLNB positive melanoma patients with and without complete lymph node dissection: A multicenter randomized DECOD trial. (Ulikie Leiter).
8:00pm - 10:00pm Dinner
9:00am - 10:00am Head and Neck Cancer
Moderators: Adrian Qasem, MD and Hazem Abdulaleh, MD
9:00 am - 9:15am
Speaker: Nader Al-Rouil, MD
-Abstract LBA3: Elective versus therapeutic neck dissection in the clinically node negative early oral cancer: A Randomised control trial (RCT). (Anil D'Cruz)
9:15am - 9:30am
Speaker: Areej Abu Sheikha, MD
-Abstract 6009: PET-NECK: A multicenter randomized phase III controlled trial (RCT) comparing PET-CT guided active surveillance with planned neck dissection (ND) for locally advanced (N2/N3) nodal metastases (LANM) in patients with head and neck squamous cell cancer (HNSCC) treated with primary radical chemoradiotherapy (CRT). (Hisham Mohamed Mehmeha).
9:30am - 9:45am
Speaker: Issa Mohamad, MD
-Abstract 6000: Phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCC/H): NSC Clinical Trials Group HN-6 trial. (Lillian L. Sui)
9:45am - 10:00am Discussion
**Saturday, August 01, 2015**

### 10:00am - 10:35am  
**Genitourinary (Prostate) Cancer**  
**Moderators:** Faeq Madanat, MD and Mohammad Salameh, MD

- **10:00am - 10:20am**  
  **Speaker:** Basel Al Haj Ala, MD  
  - Abstract 5001: Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476). (Nicholas David James)

- **10:20am - 10:35am**  
  **Speaker:** Belal Alhawwari, MD  
  - Abstract 5006: Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for biological relapse (BR) after radical prostatectomy (RP). Results of the GETSUG-AFU 16 phase III randomized trial—NCT00843745. (Christian Carie)

### 10:35am - 11:00am  
**Break**

### 11:00am - 12:00pm  
**Lymphoma and Plasma Cell Disorders**  
**Moderators:** Ahmad Othman, MD and Lina Marei, MD

- **11:00am - 11:15am**  
  **Speaker:** Kamal Al-rabi, MD  
  - Abstract LBA8502: GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma. (Laurel Helen Sehn)

- **11:15am - 11:45am**  
  **Speaker:** Sameer Yaser, MD  
  - Abstract 8508: ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without  
  - elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). (Sagar Lonial)

- **11:45am - 12:00pm**  
  **Discussion**
Organizing Committee
Sana Al Sukhun, MD, MSc
Samah Hashem, MD
Mohammad Salameh, MD
Mahmoud Al-Mazi, MD
Fayez Thibishat, MD
Faeq Madanat, MD
Salah Halasheh, MD

Guest Faculty
Rolf Stahel, MD - Switzerland
Fadi Farhat, MD - Lebanon
Munir Soliman, MD - Iraq
Tahseen Al-Rubaisi, MD - Iraq

Local Faculty
Abdullah Abbadi, MD - Jordan
Abdulwahab Al-Rashdan, MD - Jordan
Abdulmajeed Dayyat, MD - Jordan
Adnan Qasem, MD - Jordan
Ahmad Othman, MD - Jordan
Ahmad Talhat, MD - Jordan
Avay Abu Sheaheh, MD - Jordan
Basil Al-Haj Ali, MD - Jordan
Belal Al-Heeravi, MD - Jordan
Faeq Madanat, MD - Jordan
Fayez Thibishat, MD - Jordan
Ghadeer Abdeen, MD - Jordan
Hazem Abdullah, MD - Jordan
Issa Mohamad, MD - Jordan
Kamal Al-Rabi, MD - Jordan
Khouloud Al-Aqaim, MD - Jordan
Lina Marei, MD - Jordan
Mahmoud Al-Mazi, MD - Jordan
Majid Barakat, MD - Jordan
Mohammad Salameh, MD - Jordan
Muhammad Basem Hamdan, MD - Jordan
Nabil Al-Rash, MD - Jordan
Nader Al-Boice, MD - Jordan
Rasmi Mubarak, MD - Jordan
Salah Al-Absi, MD - Jordan
Salah Halasheh, MD - Jordan
Sameer Faser, MD - Jordan
Samah Hashem, MD - Jordan
Samir Khattab, MD - Jordan
Samir Rabat, MD - Jordan
Sana Al Sukhun, MD, MSc - Jordan